Compound 78c

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Astellas Foundation for Research on Metabolic Disorders and 2 more

Animals1

Outcomes

Gland size

upin mice1

1 study

Compound 78c increases gland size in mice.
“pharmacological inhibition of CD38 (using 78c) in aged mice, restores meibomian cellular NAD levels, rescues intracrine activity, suppresses inflammatory signatures, and promotes recovery of gland size.”
Animalsin aged micemeibomian gland
NAD boosting mediated by CD38 inhibition drives reversal of a pathological vicious cycle of intracrine activity and inflammation in eyelid meibomian gland dysfunction
eLife25 Mar 2026Preprint

Inflammation

downin mice1

1 study

Compound 78c decreases inflammation in mice.
“pharmacological inhibition of CD38 (using 78c) in aged mice, restores meibomian cellular NAD levels, rescues intracrine activity, suppresses inflammatory signatures”
Animalsin aged micemeibomian gland
NAD boosting mediated by CD38 inhibition drives reversal of a pathological vicious cycle of intracrine activity and inflammation in eyelid meibomian gland dysfunction
eLife25 Mar 2026Preprint

Latest

1 in 12 months

eLife25 Mar

NAD boosting mediated by CD38 inhibition drives reversal of a pathological vicious cycle of intracrine activity and inflammation in eyelid meibomian gland dysfunction

Preprint: experiments in miceInterventions

Paper

Compound 78c

Outcomes

Latest

NAD boosting mediated by CD38 inhibition drives reversal of a pathological vicious cycle of intracrine activity and inflammation in eyelid meibomian gland dysfunction

Related